FindTrial
Sign In

ABT-888

DRUG15 trials

Sponsors

AbbVie, National Cancer Institute (NCI), AbbVie (prior sponsor, Abbott), Steven J Isakoff, MD, PhD, QuantumLeap Healthcare Collaborative

Conditions

AngiosarcomaAstrocytomaBRCA1 Gene MutationBrain DiseasesBrain NeoplasmsBreast CancerBreast NeoplasmsBreast Tumors

Phase 1

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
CompletedNCT00526617
AbbVieBreast Cancer, Fallopian Tube Cancer, Hepatocellular Carcinoma +4
Start: 2007-08-31Updated: 2017-11-21
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas
CompletedNCT00553189
National Cancer Institute (NCI)Lymphomas, Solid Tumors
Start: 2007-08-09End: 2011-09-28Updated: 2017-07-02
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
CompletedNCT00649207
AbbVie (prior sponsor, Abbott)Brain Diseases, Brain Neoplasms, Central Nervous System Diseases +2
Start: 2008-03-31End: 2013-03-31Updated: 2017-11-21
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
CompletedNCT00994071
National Cancer Institute (NCI)Astrocytoma, Ependymoma, Medulloblastoma +2
Start: 2009-09-22End: 2013-03-19Updated: 2019-12-09
A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer
CompletedNCT01085422
AbbVie (prior sponsor, Abbott)Prostate Cancer
Start: 2010-04-30End: 2011-06-30Updated: 2017-11-21
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems
WithdrawnNCT01419548
National Cancer Institute (NCI)Neoplasms
Start: 2011-07-29End: 2011-11-18Updated: 2017-07-02
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer
CompletedNCT01445522
National Cancer Institute (NCI)Lymphoma, Neoplasms
Start: 2008-12-03End: 2012-07-03Updated: 2019-12-17
ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
CompletedNCT01489865
Georgetown UniversityMetastatic Pancreatic Cancer
Start: 2011-01-03End: 2023-12-07Updated: 2025-11-06

Phase 2

A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
CompletedNCT00804908
AbbVie (prior sponsor, Abbott)Melanoma, Metastatic Melanoma, Skin Cancer
Start: 2009-02-28End: 2016-01-31Updated: 2018-06-06
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
CompletedNCT01009788
Steven J Isakoff, MD, PhDBRCA1 Gene Mutation, brca2 Gene Mutation, Breast Cancer +1
Start: 2009-11-30End: 2015-09-30Updated: 2025-03-14
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RecruitingNCT01042379
QuantumLeap Healthcare CollaborativeAngiosarcoma, Breast Cancer, Breast Neoplasms +8
Start: 2010-03-01End: 2031-12-01Target: 5000Updated: 2026-03-13
A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer
CompletedNCT01051596
Georgetown UniversityColorectal Cancer
Start: 2009-09-30End: 2013-12-31Updated: 2019-04-02
A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer
CompletedNCT01113957
AbbVie (prior sponsor, Abbott)Ovarian Cancer
Start: 2010-03-31End: 2013-06-30Updated: 2018-06-06
ABT-888 and Temozolomide for Liver Cancer
TerminatedNCT01205828
Georgetown UniversityHepatocellular Carcinoma
Start: 2010-08-31End: 2014-10-31Updated: 2025-02-12
Phase II ABT-888 With Cyclophosphamide
CompletedNCT01306032
National Cancer Institute (NCI)Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer +2
Start: 2011-01-12End: 2016-12-15Updated: 2017-04-26

Related Papers

Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer.
2026-03-25
Abstract PS3-11-10: Neoadjuvant HSP90 inhibition with ganetespib significantly improves distant relapse-free survival in I-SPY2 patients with HER2-negative breast cancer with low expression of immune genes and no DNA repair deficiency
Clinical Cancer Research2026-02-17
Abstract PS1-01-09: Real-time monitoring for drug-induced interstitial lung disease with Trastuzumab Deruxtecan and Rilvegostomig combination therapy prevents persistent, symptomatic disease: Safety insights from the I-SPY2.2 platform trial
Clinical Cancer Research2026-02-17
Abstract RF5-06: Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788: Results from the I-SPY2.2 trial
Clinical Cancer Research2026-02-17
Abstract PS2-11-06: Quiescent-like phenotype characterizes treatment-resistant early-stage HER2-negative breast cancers and suggests novel therapeutic targets; analysis of over 2000 patients from the I-SPY2 trial
Clinical Cancer Research2026-02-17
CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial.
2025-10-24
Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial
Frontiers in Oncology2025-07-24
A two-stage dual-task learning strategy for early prediction of pathological complete response to neoadjuvant chemotherapy for breast cancer using dynamic contrast-enhanced magnetic resonance images
Physics in Medicine and Biology2025-07-101 citations
Radiomics-based Machine Learning Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Using Physiologically Decomposed Diffusion-weighted MRI.
2025-07-012 citations
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial
Breast Cancer Research2025-06-233 citations
Abstract P2-01-23: A 140-gene Machine Learning Classifier Predicts Survival and Response to Chemotherapy and Immunotherapy in 2500 TNBC
Clinical Cancer Research2025-06-13
Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.
Journal of Clinical Oncology2025-05-283 citations
Serum estradiol (sE2) levels in premenopausal (PreM) women receiving neoadjuvant ovarian function suppression (OFS) with the oral SERD amcenestrant, alone, or in combination with letrozole or abemaciclib in the I-SPY2 Endocrine Optimization Pilot (EOP).
Journal of Clinical Oncology2025-05-28
I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC).
Journal of Clinical Oncology2025-05-28
Early adverse symptoms to predict response to treatment among patients in the I-SPY trial.
Journal of Clinical Oncology2025-05-28
Causal analyses of the impact of comorbid conditions and concomitant medications on response to neoadjuvant chemotherapy in breast cancer: analysis of a multicenter prospective cohort study (CANTO).
2025-05-15
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer
Breast Cancer Research and Treatment2024-12-031 citations
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.
2024-11-299 citations
Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer.
2024-09-2710 citations
Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Nature Medicine2024-09-1427 citations

73 more papers not shown